These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28762015)

  • 1. Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis.
    Buchanan J; Wordsworth S; Clifford R; Robbe P; Taylor JC; Schuh A; Knight SJL
    Pharmacoeconomics; 2017 Aug; 35(8):845-858. PubMed ID: 28762015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
    Sinha R; Redekop WK
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e131-e142. PubMed ID: 29398648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Kang DW; Wang L; Short NJ; Ferrajoli A; Wang Y; Zhou S; Shen C
    Pharmacoeconomics; 2024 Apr; 42(4):409-418. PubMed ID: 38184494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Ibrutinib for Chronic Lymphocytic Leukemia Treatment in India: Is Evidence Really at Crossroads?
    Jyani G; Gupta N
    Value Health Reg Issues; 2024 Jul; 42():100991. PubMed ID: 38723366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
    Shanafelt TD; Borah BJ; Finnes HD; Chaffee KG; Ding W; Leis JF; Chanan-Khan AA; Parikh SA; Slager SL; Kay NE; Call TG
    J Oncol Pract; 2015 May; 11(3):252-8. PubMed ID: 25804983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.
    Barnes JI; Divi V; Begaye A; Wong R; Coutre S; Owens DK; Goldhaber-Fiebert JD
    Blood Adv; 2018 Aug; 2(15):1946-1956. PubMed ID: 30097461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
    Becker U; Briggs AH; Moreno SG; Ray JA; Ngo P; Samanta K
    Value Health; 2016 Jun; 19(4):374-82. PubMed ID: 27325329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Carroll C; Stevens J; Simpson E; Thokala P; Wong R; Wright J; Auer R
    Pharmacoeconomics; 2019 Jan; 37(1):7-18. PubMed ID: 29951793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.
    Patel KK; Isufi I; Kothari S; Davidoff AJ; Gross CP; Huntington SF
    Blood; 2020 Oct; 136(17):1946-1955. PubMed ID: 32518952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
    Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
    Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
    Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse.
    Adena M; Houltram J; Mulligan SP; Todd C; Malanos G
    Pharmacoeconomics; 2014 Feb; 32(2):193-207. PubMed ID: 24442832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.
    Vreman RA; Geenen JW; Hövels AM; Goettsch WG; Leufkens HGM; Al MJ
    Appl Health Econ Health Policy; 2019 Dec; 17(6):883-893. PubMed ID: 31317510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
    Walker S; Palmer S; Erhorn S; Brent S; Dyker A; Ferrie L; Horsley W; Macfarlane K; White S; Thomas S
    Health Technol Assess; 2009 Jun; 13 Suppl 1():35-40. PubMed ID: 19567212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
    Wierda WG; Byrd JC; O'Brien S; Coutre S; Barr PM; Furman RR; Kipps TJ; Burger JA; Stevens DA; Sharman J; Ghia P; Flinn IW; Zhou C; Ninomoto J; James DF; Tam CS
    Br J Haematol; 2019 Jul; 186(1):184-188. PubMed ID: 30740654
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
    Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
    Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia.
    Vu M; Degeling K; Thompson ER; Blombery P; Westerman D; IJzerman MJ
    Appl Health Econ Health Policy; 2024 Jan; 22(1):107-122. PubMed ID: 37608228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
    Kater AP; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Brieghel C; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Niemann CU
    Lancet Oncol; 2022 Jun; 23(6):818-828. PubMed ID: 35654052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.